Arbutus Biopharma (ABUS) Tops Q1 EPS by 91c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of $0.87, $0.91 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $179.23 million versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• China Southern To Buy Boeing Planes For At Least $3.62b - Bloomberg
• Northland Downgrades Quantum Corp. (QMCO) to Market Perform